Items where authors include "Iveson, T"

Article

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. The Lancet Oncology, 22 (7). e288-e289. ISSN 1470-2045

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 22 (5). pp. 690-701. ISSN 1470-2045

Argiles, G, Tabernero, J, Labianca, R et al. (10 more authors) (2020) Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 31 (10). pp. 1291-1305. ISSN 0923-7534

Primrose, JN, Fox, RP, Palmer, DH et al. (26 more authors) (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology, 20 (5). pp. 663-673. ISSN 1213-9432

Davidson, M, Chau, I, Cunningham, D et al. (5 more authors) (2017) Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 9 (8). pp. 333-340. ISSN 1948-5204

Proceedings Paper

Shiu, K-K, Seligmann, JF orcid.org/0000-0003-4379-6005, Graham, J et al. (15 more authors) (2022) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting I, 03-07 Jun 2022, Chicago, USA. American Society of Clinical Oncology .